|
CBFB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.33409999398305E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.06910036379304E-11 |
| Normal-vs-Stage2 |
2.100600E-01 |
| Normal-vs-Stage3 |
1.00979999995143E-06 |
| Normal-vs-Stage4 |
1.76080000025003E-07 |
| Stage1-vs-Stage2 |
1.603580E-03 |
| Stage1-vs-Stage3 |
1.669450E-01 |
| Stage1-vs-Stage4 |
7.256000E-01 |
| Stage2-vs-Stage3 |
3.099800E-02 |
| Stage2-vs-Stage4 |
1.156390E-02 |
| Stage3-vs-Stage4 |
4.141800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.1305956998674E-11 |
| Normal-vs-AfricanAmerican |
2.570000E-04 |
| Normal-vs-Asian |
2.39579999999906E-05 |
| Caucasian-vs-AfricanAmerican |
5.557000E-01 |
| Caucasian-vs-Asian |
9.146600E-01 |
| AfricanAmerican-vs-Asian |
5.563200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.77370000037969E-07 |
| Normal-vs-Female |
5.13219466924397E-11 |
| Male-vs-Female |
3.275000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.18356452311264E-12 |
| Normal-vs-Age(41-60Yrs) |
2.24140000004702E-07 |
| Normal-vs-Age(61-80Yrs) |
6.189500E-04 |
| Normal-vs-Age(81-100Yrs) |
1.519770E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.700200E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.279900E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.610000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.816000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.537600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.941200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.165600E-01 |
| Classical-VS-Follicular |
1.52100554373646E-14 |
| Classical-VS-Other |
7.312200E-01 |
| Classical-VS-Normal |
1.63025148935958E-12 |
| Tall-VS-Follicular |
9.96439999999543E-05 |
| Tall-VS-Other |
9.402600E-01 |
| Tall-VS-Normal |
1.16480000000863E-06 |
| Follicular-VS-Other |
3.195700E-02 |
| Follicular-VS-Normal |
9.718400E-01 |
| Other-VS-Normal |
6.884000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.626800E-04 |
| Normal-vs-N1 |
3.25569999848341E-08 |
| N0-vs-N1 |
3.604300E-03 |
|
|
